Harnessing synthetic biology to develop novel psychedelic therapies
PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion pe...
Gespeichert in:
| Veröffentlicht in: | Trends in biotechnology (Regular ed.) 2023-04, Vol.41 (4), p.586-587 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 587 |
|---|---|
| container_issue | 4 |
| container_start_page | 586 |
| container_title | Trends in biotechnology (Regular ed.) |
| container_volume | 41 |
| creator | Jones, J. Andrew Spigarelli, Michael G. |
| description | PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion people globally.KEY FACTS: Globally, individuals with untreated mental health conditions have a median life expectancy that is approximately 10 years shorter than mentally healthy individuals. Recombinant psilocybin biosynthesis was first reported in 2018 in Aspergillus nidulans, followed by the first bacterial biosynthesis in Escherichia coli in 2019 and a 2020 study in Saccharomyces cerevisiae.Acknowledgments Figure is created with BioRender.com.Declaration of interests J.A.J. is the chairman of the scientific advisory board and a significant stakeholder at PsyBio Therapeutics. |
| doi_str_mv | 10.1016/j.tibtech.2022.12.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758354083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167779922003110</els_id><sourcerecordid>2758354083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-a6b46c3583686cb9372e3b7a6e1b454b5a4b99098c5d1d72918e944a5c40837e3</originalsourceid><addsrcrecordid>eNqF0E1rGzEQgGFRGmrH7U9oWOill93qW6tTCaZJCoZe0rOQtGNbZr3aSmuD_31k7OSQS09zeWYkXoS-EtwQTOSPXTMFN4HfNhRT2hDaYMw-oDlpla4Z1vIjmhenaqW0nqHbnHe4CKXJJzRjUkhFWj5HyyebBsg5DJsqn4ZpC1PwlQuxj5tTNcWqgyP0cayGWGY15pPfQgd9QcUmOwbIn9HN2vYZvlznAv19-PW8fKpXfx5_L-9XtWecTLWVjkvPRMtkK73TTFFgTlkJxHHBnbDcaY1160VHOkU1aUFzboXnuGUK2AJ9v9wdU_x3gDyZfcge-t4OEA_ZUFVuizMu9Ns7uouHNJTfFdUqSoVmoihxUT7FnBOszZjC3qaTIdicK5uduVY258qGUFMalr276_WD20P3tvWatYCfFwAlxzFAMtkHGDx0IYGfTBfDf554ARLEj4M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2787225935</pqid></control><display><type>article</type><title>Harnessing synthetic biology to develop novel psychedelic therapies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jones, J. Andrew ; Spigarelli, Michael G.</creator><creatorcontrib>Jones, J. Andrew ; Spigarelli, Michael G.</creatorcontrib><description>PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion people globally.KEY FACTS: Globally, individuals with untreated mental health conditions have a median life expectancy that is approximately 10 years shorter than mentally healthy individuals. Recombinant psilocybin biosynthesis was first reported in 2018 in Aspergillus nidulans, followed by the first bacterial biosynthesis in Escherichia coli in 2019 and a 2020 study in Saccharomyces cerevisiae.Acknowledgments Figure is created with BioRender.com.Declaration of interests J.A.J. is the chairman of the scientific advisory board and a significant stakeholder at PsyBio Therapeutics.</description><identifier>ISSN: 0167-7799</identifier><identifier>EISSN: 1879-3096</identifier><identifier>DOI: 10.1016/j.tibtech.2022.12.003</identifier><identifier>PMID: 36567184</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biosynthesis ; Chemical synthesis ; Drug dosages ; E coli ; Hallucinogens - pharmacology ; Hallucinogens - therapeutic use ; Life expectancy ; Life span ; Mental depression ; Mental disorders ; Mental health ; Post traumatic stress disorder ; Psilocybin ; Psychedelic drugs ; Synthetic Biology ; Tryptamine ; Tryptamines</subject><ispartof>Trends in biotechnology (Regular ed.), 2023-04, Vol.41 (4), p.586-587</ispartof><rights>2022 Elsevier Ltd</rights><rights>2022. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c341t-a6b46c3583686cb9372e3b7a6e1b454b5a4b99098c5d1d72918e944a5c40837e3</cites><orcidid>0000-0002-9068-2126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167779922003110$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36567184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, J. Andrew</creatorcontrib><creatorcontrib>Spigarelli, Michael G.</creatorcontrib><title>Harnessing synthetic biology to develop novel psychedelic therapies</title><title>Trends in biotechnology (Regular ed.)</title><addtitle>Trends Biotechnol</addtitle><description>PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion people globally.KEY FACTS: Globally, individuals with untreated mental health conditions have a median life expectancy that is approximately 10 years shorter than mentally healthy individuals. Recombinant psilocybin biosynthesis was first reported in 2018 in Aspergillus nidulans, followed by the first bacterial biosynthesis in Escherichia coli in 2019 and a 2020 study in Saccharomyces cerevisiae.Acknowledgments Figure is created with BioRender.com.Declaration of interests J.A.J. is the chairman of the scientific advisory board and a significant stakeholder at PsyBio Therapeutics.</description><subject>Biosynthesis</subject><subject>Chemical synthesis</subject><subject>Drug dosages</subject><subject>E coli</subject><subject>Hallucinogens - pharmacology</subject><subject>Hallucinogens - therapeutic use</subject><subject>Life expectancy</subject><subject>Life span</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Mental health</subject><subject>Post traumatic stress disorder</subject><subject>Psilocybin</subject><subject>Psychedelic drugs</subject><subject>Synthetic Biology</subject><subject>Tryptamine</subject><subject>Tryptamines</subject><issn>0167-7799</issn><issn>1879-3096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0E1rGzEQgGFRGmrH7U9oWOill93qW6tTCaZJCoZe0rOQtGNbZr3aSmuD_31k7OSQS09zeWYkXoS-EtwQTOSPXTMFN4HfNhRT2hDaYMw-oDlpla4Z1vIjmhenaqW0nqHbnHe4CKXJJzRjUkhFWj5HyyebBsg5DJsqn4ZpC1PwlQuxj5tTNcWqgyP0cayGWGY15pPfQgd9QcUmOwbIn9HN2vYZvlznAv19-PW8fKpXfx5_L-9XtWecTLWVjkvPRMtkK73TTFFgTlkJxHHBnbDcaY1160VHOkU1aUFzboXnuGUK2AJ9v9wdU_x3gDyZfcge-t4OEA_ZUFVuizMu9Ns7uouHNJTfFdUqSoVmoihxUT7FnBOszZjC3qaTIdicK5uduVY258qGUFMalr276_WD20P3tvWatYCfFwAlxzFAMtkHGDx0IYGfTBfDf554ARLEj4M</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Jones, J. Andrew</creator><creator>Spigarelli, Michael G.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QF</scope><scope>7QO</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8BQ</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F28</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H8D</scope><scope>H8G</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L6V</scope><scope>L7M</scope><scope>LK8</scope><scope>L~C</scope><scope>L~D</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9068-2126</orcidid></search><sort><creationdate>202304</creationdate><title>Harnessing synthetic biology to develop novel psychedelic therapies</title><author>Jones, J. Andrew ; Spigarelli, Michael G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-a6b46c3583686cb9372e3b7a6e1b454b5a4b99098c5d1d72918e944a5c40837e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biosynthesis</topic><topic>Chemical synthesis</topic><topic>Drug dosages</topic><topic>E coli</topic><topic>Hallucinogens - pharmacology</topic><topic>Hallucinogens - therapeutic use</topic><topic>Life expectancy</topic><topic>Life span</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Mental health</topic><topic>Post traumatic stress disorder</topic><topic>Psilocybin</topic><topic>Psychedelic drugs</topic><topic>Synthetic Biology</topic><topic>Tryptamine</topic><topic>Tryptamines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, J. Andrew</creatorcontrib><creatorcontrib>Spigarelli, Michael G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in biotechnology (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, J. Andrew</au><au>Spigarelli, Michael G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Harnessing synthetic biology to develop novel psychedelic therapies</atitle><jtitle>Trends in biotechnology (Regular ed.)</jtitle><addtitle>Trends Biotechnol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>41</volume><issue>4</issue><spage>586</spage><epage>587</epage><pages>586-587</pages><issn>0167-7799</issn><eissn>1879-3096</eissn><abstract>PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion people globally.KEY FACTS: Globally, individuals with untreated mental health conditions have a median life expectancy that is approximately 10 years shorter than mentally healthy individuals. Recombinant psilocybin biosynthesis was first reported in 2018 in Aspergillus nidulans, followed by the first bacterial biosynthesis in Escherichia coli in 2019 and a 2020 study in Saccharomyces cerevisiae.Acknowledgments Figure is created with BioRender.com.Declaration of interests J.A.J. is the chairman of the scientific advisory board and a significant stakeholder at PsyBio Therapeutics.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36567184</pmid><doi>10.1016/j.tibtech.2022.12.003</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-9068-2126</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-7799 |
| ispartof | Trends in biotechnology (Regular ed.), 2023-04, Vol.41 (4), p.586-587 |
| issn | 0167-7799 1879-3096 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2758354083 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biosynthesis Chemical synthesis Drug dosages E coli Hallucinogens - pharmacology Hallucinogens - therapeutic use Life expectancy Life span Mental depression Mental disorders Mental health Post traumatic stress disorder Psilocybin Psychedelic drugs Synthetic Biology Tryptamine Tryptamines |
| title | Harnessing synthetic biology to develop novel psychedelic therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A32%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Harnessing%20synthetic%20biology%20to%20develop%20novel%20psychedelic%20therapies&rft.jtitle=Trends%20in%20biotechnology%20(Regular%20ed.)&rft.au=Jones,%20J.%20Andrew&rft.date=2023-04&rft.volume=41&rft.issue=4&rft.spage=586&rft.epage=587&rft.pages=586-587&rft.issn=0167-7799&rft.eissn=1879-3096&rft_id=info:doi/10.1016/j.tibtech.2022.12.003&rft_dat=%3Cproquest_cross%3E2758354083%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2787225935&rft_id=info:pmid/36567184&rft_els_id=S0167779922003110&rfr_iscdi=true |